Vascepa® Granted Priority Review Status from Health Canada
BioTech Gate,
New Drug Submission (NDS) for Vascepa in Canada Anticipated to Be Filed in April 2019 by HLS Therapeutics, Under Agreement with…
New Drug Submission (NDS) for Vascepa in Canada Anticipated to Be Filed in April 2019 by HLS Therapeutics, Under Agreement with…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
New Drug Submission (NDS) for Vascepa in Canada Anticipated to Be Filed in April 2019 by HLS Therapeutics, Under Agreement with…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
Anti-Oxidant Effects of Eicosapentaenoic Acid Data at Pharmacologic Concentrations Also Presented BEDMINSTER, N.J., and DUBLIN…
Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology's 68th…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health…
SOURCE Amarin Corporation plc Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show…
SOURCE Amarin Corporation plc Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show…
SOURCE Amarin Corporation plc Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show…
SOURCE Amarin Corporation plc Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show…
Amarin Corporation plc (NASDAQ: AMRN), presented new data from its landmark cardiovascular outcomes study of its prescription…
/PRNewswire/ -- Amarin Corporation PLC (NASDAQ: AMRN), presented new data from its landmark cardiovascular outcomes study of…